Skip to content
Open access

AI-enabled drug repurposing in Alzheimer’s disease: from computational nomination to pharmacological proof

Oct 2026 · Frontiers in Pharmacology · Vol 17 · 0 citations · 54 references

TL;DR

Rather than cataloguing methods and candidates, this work appraise leading drugs at the individual-molecule level and proposes explicit criteria for progression from computational nomination to clinical testing, which defines seven requirements for clinical progression.

Abstract

Artificial intelligence (AI) has expanded the scale and speed of drug repurposing in Alzheimer’s disease (AD). Transcriptomic signature matching, network-based systems pharmacology, real-world data pharmacoepidemiology and multi-omics machine learning have generated hundreds of candidate drugs, while repurposed agents account for 35% (56 of 158) of drugs and 42% (15 of 36) of Phase 3 agents in the 2026 AD pipeline. Clinical translation, however, remains unproven. Randomised trials of GLP-1 receptor agonists illustrate the gap between prioritisation and therapeutic proof: semaglutide did not slow clinical progression in evoke and evoke+, while liraglutide did not improve the primary FDG-PET endpoint in ELAD. We examine four complementary evidence domains, defining what each can and cannot establish, and position large language models as a cross-cutting tool for evidence synthesis and knowledge-graph reasoning rather than an independent source of biological evidence. Rather than cataloguing methods and candidates, we appraise leading drugs at the individual-molecule level and propose explicit criteria for progression from computational nomination to clinical testing. The framework defines seven requirements for clinical progression: disease-stage matching, adequate site-of-action exposure, including CNS exposure for central mechanisms, mechanistic validation in human-relevant models, biomarker-stratified trial design, convergence across independent evidence domains, causal inference with explicit boundary conditions, and mechanism-aligned endpoints with predefined stopping rules. AI has improved candidate prioritisation in AD, but clinical value will depend on converting ranked hypotheses into pharmacologically plausible and prospectively testable programmes.

Read PDF

Similar papers

#gene editing Open access Oct 2026

Alzheimer's disease target and drug discovery by leveraging multiomics and electronic health data.

Despite prolific genomic data from individuals with Alzheimer's disease (AD), translation into treatments has lagged. Here we applied Mendelian randomization to multiple AD genome-wide association studies and functional multiomics datasets to nominate druggable targets, identifying 19 targets for individuals of Europea...

Yuan Hou, Yi-Chen Li, Peng-Yue Zhang et al. · 0 citations
Review Open access Oct 2026

Artificial Intelligence-Assisted Drug Discovery for Neurodegenerative Diseases: Integration of Machine Learning, Molecular Docking, and Systems Pharmacology

Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) remain among the most therapeutically intractable areas of medicine, with decades of high clinical-trial attrition and an almost complete absence of disease-modifying therapies. Conventional dr...

A. Kumar, D. Vishwakarma · 0 citations
Open access Nov 2026

RepurposeAD: Knowledge Graph-Guided LLM Reasoning for Alzheimer’s Drug Repurposing

Background/Objectives: Alzheimer’s disease (AD) drug development continues to suffer from high late-stage attrition and narrow mechanistic diversity, which makes the systematic repurposing of approved compounds an urgent priority. Existing computational repurposing methods operate on fragmented biomedical knowledge, ra...

Shahidur Rahoman Sohag, Syed Murtoza Mushrul Pasha, Hossny Ghanem et al. · 0 citations
Review Oct 2026

AI-Driven Discovery and Delivery Systems for Anti-Parkinsonian Agents.

Parkinson's disease is the second most widely diagnosed neurodegenerative disorder in the world, affecting more than 10 million people, with current drug therapies for treatment providing limited symptomatic relief and no effect on stopping disease progression. The integration of AI and Pharmaceutical Sciences has led...

P. Tiwari, S. Kartik, Kriti Rohilla et al. · 0 citations
Review Sep 2026

Advances in Machine Learning for Drug Repurposing: From Methodologies to Precision Medicine with Case Studies in COVID-19, Parkinson's Disease, and Cancer.

This review investigates recent advances in machine learning (ML) for drug repurposing, with applications spanning COVID-19, Parkinson's disease, and cancer. We provide a methodological taxonomy of ML techniques including supervised learning (e.g., random forests, SVMs), unsupervised clustering and dimensionality reduc...

Betel Gurara, Saron Gebremichael, Hana Sheto et al. · 0 citations
#artificial intelligence Preprint Oct 2026

DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI Scientists

Drug target discovery requires distinguishing molecules that causally drive disease from those that are merely associated with it. Training and evaluating AI agents to perform this workflow end-to-end is difficult because real world biobanks lack known causal ground truth and participant-level data is access controlled...

Samuel Margolis, P. Schmiedmayer, A.-J. Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.